Desvenlafaxine extended-release tablets in major depressive disorder and hot flushes: a profile of its use

<div>Compliance with ethical standards</div><div><br></div><div><i>Funding</i>: The preparation of this review was not supported by any external funding.</div><div><br></div><div><i>Conflicts of interest:</i> Lesley Scott is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.</div><div> </div><div>Additional information about this Adis Drug Review can be found<b> <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a>.</b></div><div><br></div><div>Abstract</div><div><br></div><div>Oral desvenlafaxine extended-release [Deller (Brazil); Pristiq (USA)] is a second-generation, selective serotonin-noradrenalin reuptake inhibitor that is indicated for the treatment of major depressive disorder (MDD) in adults. In this population, desvenlafaxine is an effective and generally well tolerated treatment, significantly improving symptoms of depression and functional outcomes compared with placebo in 8-week double-blind trials, with these benefits maintained during longer-term therapy. In addition, desvenlafaxine is an effective and generally well tolerated treatment in postmenopausal women with vasomotor symptoms (VMS), significantly reducing the number and severity of hot flushes during 12-week trials, with these benefits maintained during longer-term therapy. Access to the full article can be found <b><a href="https://link.springer.com/article/10.1007/s40267-017-0439-1">here</a>.</b></div><div><br></div><div>© Springer International Publishing AG, part of Springer Nature 2017